<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517424</url>
  </required_header>
  <id_info>
    <org_study_id>CMJP-1</org_study_id>
    <nct_id>NCT02517424</nct_id>
  </id_info>
  <brief_title>Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder</brief_title>
  <official_title>Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tilray</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tilray</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of vaporized cannabis in
      participants with chronic, treatment-resistant posttraumatic stress disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to end of Stage 1 in posttraumatic stress disorder symptoms via Clinician Administered PTSD Scale (CAPS) for Diagnostic and Statistical Manual of Mental Disorders (DSM)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD symptoms during Stage 1 using PTSD Checklist 5 (PCL 5).</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD symptoms during Stage 2 using PCL 5 checklist.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of anxiety in Stage 1 via the Inventory of Depression and Anxiety Scale</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of anxiety in Stage 2 via the Inventory of Depression and Anxiety Scale</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of depression in Stage 2 via the Inventory of Depression and Anxiety Scale</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychosocial functioning in Stage 2 via the Inventory of Psychosocial Functioning</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preference for Stage 1 vs Stage 2 cannabis using the Long-term Follow-up Questionnaire</measure>
    <time_frame>34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD symptoms via CAPS assessment over Stage 1 and 2.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTSD symptoms via PCL-5 assessment during abstinence periods.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality via actigraphy measures</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality via Insomnia Severity Index</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality via Sleep Diary entries</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulse rate following controlled self-administration of investigational product</measure>
    <time_frame>Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cannabis withdrawal symptoms</measure>
    <time_frame>For 2 weeks after administration period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in problems associated with cannabis use based on Cannabis Use Disorders Identification Test</measure>
    <time_frame>36 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subjective drug effect via completion of the Drug Effect Questionnaire</measure>
    <time_frame>For 3 weeks in stage 1 and stage 2, respectively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence of suicidal thoughts or behaviors via Columbia Suicide Severity Rating Scale</measure>
    <time_frame>36 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs</measure>
    <time_frame>0-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dosing compliance via diary entry and product returns</measure>
    <time_frame>0-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Abstinence compliance via urine cannabinoid levels</measure>
    <time_frame>-2 to 10 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>High THC/Low CBD Cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product will be administered via vaporization up to 2 grams per day as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC/High CBD cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product will be administered via vaporization up to 2 grams per day as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC/Low CBD cannabis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Product will be administered via vaporization up to 2 grams per day as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High THC/Low CBD Cannabis</intervention_name>
    <description>Dried cannabis</description>
    <arm_group_label>High THC/Low CBD Cannabis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High THC/High CBD Cannabis</intervention_name>
    <description>Dried cannabis</description>
    <arm_group_label>High THC/High CBD cannabis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low THC/Low CBD Cannabis</intervention_name>
    <description>Dried cannabis</description>
    <arm_group_label>Low THC/Low CBD cannabis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet DSM-5 criteria for chronic PTSD of at least six months duration.

          2. Have PTSD of moderate severity as measured by a score of &gt;= 40 on the PCL-5 at the
             time of baseline assessment.

          3. Have treatment resistant PTSD defined as meeting DSM-5 diagnostic criteria for PTSD
             after failing on, or being unable to tolerate, Health Canada-approved medication or
             empirically supported psychotherapy for PTSD of adequate dose and duration, as
             determined on a case-by-case basis by the site investigators.

          4. Are at least 18 years old.

          5. Are willing to commit to medication dosing and delivery method, to completing
             evaluation instruments, and to attending all study visits.

          6. Agree to use only cannabis provided by study staff until the end of Stage 2 and agree
             to required cessation periods for the duration of the study.

          7. Report no current hazardous cannabis use, as defined by a score of &lt; 8 on the CUDIT-R
             at time of screening.

          8. Abstain from cannabis during the 2-week baseline assessment period as biochemically
             verified via urine cannabinoid concentrations.

          9. Agree to keep all study cannabis stored in a secure location and not to
             share/distribute cannabis to any other individual.

         10. Be stable on medications and/or psychotherapy for PTSD for at least one month prior to
             study entry.

         11. Agree to report any changes in medication or psychotherapy treatment regimen during
             the study to study staff.

         12. If female and of childbearing potential, agree to use an effective form of birth
             control during study participation.

         13. Participants must be proficient in reading English, and must be able to effectively
             communicate with the investigators and other site personnel.

         14. Agree not to participate in any other interventional clinical trials during study
             participation.

         15. Agree not to donate blood from the start of study treatment to 24 hours after the last
             dose.

         16. Agree to allow the collection of his/her gender, race, and occupation to ensure that
             the study recruits the targeted population.

        Exclusion Criteria:

          1. Are pregnant or nursing, or of child bearing potential and not practicing an effective
             means of birth control.

          2. Have a history of primary psychotic disorder, bipolar affective disorder, bipolar
             disorder with psychotic features, depressive disorder with psychotic features,
             borderline personality disorder, antisocial personality disorder, or positive family
             history (first degree relative) of psychotic disorder or bipolar affective disorder.

          3. Have any allergies to cannabis or contraindication for using cannabis.

          4. Are currently taking drugs known to be substrates for CYP 3A4 or CYP 2C19, such as
             amitriptyline, fentanyl, sufentanil, and alfentanil.

          5. Have a diagnosis of obstructive sleep apnea or a score of &gt;3 on the STOP-Bang
             questionnaire (except in cases where the participant has documented evidence of not
             having obstructive sleep apnea OR if the participant is compliant on CPAP treatment).
             Documented evidence consists of a negative result for obstructive sleep apnea on the
             completion of a formal assessment for apnea.

          6. Would present a serious suicide risk as assessed by the investigators, or who are
             likely to require psychiatric hospitalization during the course of the study.

          7. Are not able to give adequate informed consent.

          8. Are not able to attend face-to-face visits or plan to move out of the area during the
             active treatment period.

          9. Have a positive urine drug screen for opiates (unless prescribed or contained in an
             over-the-counter Health Canada approved medication), methamphetamine, cocaine and
             amphetamines or meet the DSM-5 criteria for substance use disorder (other than
             caffeine or nicotine) during Stage 1 and 2 of the study.

         10. Have signs of ischemia (defined as ST elevation or depression) or significant
             arrhythmia (defined as atrial fibrillation or flutter, ventricular fibrillation or
             flutter) on the screening electrocardiogram.

         11. Have abnormal hepatic or renal function (abnormal liver function tests or elevated
             creatinine results on the screening laboratory reports).

         12. During the 2-week screening period, are diagnosed with dissociative identity disorder
             or an eating disorder with active purging, evidence of significant, uncontrolled
             hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary,
             gastrointestinal, or neurological disease;

         13. During the 2-week screening period, meet criteria for cannabis use disorder (4 or more
             of 11 DSM-5 criteria) and continued cannabis use confirmed by urine testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Lucas, MA</last_name>
    <phone>250-722-3991</phone>
    <phone_ext>9567</phone_ext>
    <email>philippe@tilray.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaye Ong</last_name>
    <phone>250-755-6994</phone>
    <email>kaye.ong@tilray.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1V 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Walsh, PhD</last_name>
      <email>zachary.walsh@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ian Mitchell, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

